Results of nivolumab use in patients with non-small cell lung cancer in clinical practice of the N.N. Blokhin cancer research center

Abstract

The development of immune checkpoint inhibitors has altered the landscape of treatment of advanced cancers including non-small cell lung cancer (NSCLC). Nivolumab is the PD-1 inhibitor approved for the treatment of NSCLC to show a survival benefit in a randomised phase III trials. The experience of physicians in routine clinical practice is often different from those in a controlled clinical trial setting. The purpose of this analysis is to evaluate nivolumab use in real world setting. Key words: immunotherapy, non-small cell lung cancer, checkpoint inhibitors, nivolumab.